AI Article Synopsis
Article Abstract
Introduction: The Surgical Care Improvement Project (SCIP) was launched in 2005. One of the SCIP metrics includes perioperative beta-blocker guideline (CARD-2), which measures the percentage of patients on a pre-operative beta-blocker with continued use in the perioperative period. Compliance is intended to decrease rates of acute myocardial infarction (AMI) and cardiac mortality among high-risk patients. We desired to create low cost, standardized processes on an institutional level to improve compliance with the SCIP CARD-2 metric.
Methods: We assessed the impact of interventions on provider compliance with the SCIP CARD-2 metric and on simulated impact on institutional cost.
Results: We were able to improve CARD-2 compliance at one hospital within a year of intervention implementation. The hospital decreased its losses due to noncompliance in FY 2014 by $27 273.
Discussion: A relatively low cost intervention, aimed at educating providers that utilized existing infrastructure resulted in improved SCIP beta-blocker compliance. Changes in the reimbursement system made at the time of publication demonstrate that reimbursement measures are constantly in flux; tailored interventions based upon our successes may still produce similar results.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/HCM.0000000000000074 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management of perioperative thyrotoxicosis - what to do when standard therapy is contraindicated or fails?
Front Endocrinol (Lausanne)
December 2024
Department of Endocrinology, Singapore General Hospital, Singapore, Singapore.
Background: Current guidelines recommend that hyperthyroid patients should be rendered euthyroid prior to surgical procedures. These guidelines rely heavily on the use of ATDs as the primary medication, and do not give recommendations for patients who have contraindications to ATDs, or for whom standalone ATD treatment is inadequate.
Objectives: To evaluate the efficacy and safety of adjunctive pharmacological therapy and/or therapeutic plasma exchange (TPE) in the perioperative management of patients with thyrotoxicosis who were intolerant to ATD or for whom standalone ATD therapy was inadequate to achieve euthyroidism prior to surgery.
Impact of noradrenergic inhibition on neuroinflammation and pathophysiology in mouse models of Alzheimer's disease.
J Neuroinflammation
December 2024
Department of Neurosurgery, Stanford University School of Medicine, 1050 Arastradero Road, Building A, Palo Alto, Stanford, CA, 94304, United States of America.
Norepinephrine (NE) modulates cognitive function, arousal, attention, and responses to novelty and stress, and it also regulates neuroinflammation. We previously demonstrated behavioral and immunomodulatory effects of beta-adrenergic pharmacology in mouse models of Alzheimer's disease (AD). The current studies were designed to block noradrenergic signaling in 5XFAD mice through (1) chemogenetic inhibition of the locus coeruleus (LC), (2) pharmacologic blocking of β-adrenergic receptors, and (3) conditional deletion of β1- or β2-adrenergic receptors (adrb1 or adrb2) in microglia.
View Article and Find Full Text PDFBeta-Blocker Use in Patients Undergoing Non-Cardiac Surgery: A Systematic Review and Meta-Analysis.
Med Sci (Basel)
November 2024
Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico.
Background: The use of beta-blockers in the perioperative period has been widely investigated due to their potential to reduce the risk of major adverse cardiovascular and cerebrovascular events (MACCE) and mortality; yet their overall impact on various postoperative outcomes remains debated. This study constitutes a systematic review and meta-analysis of the impact of beta-blockers on mortality, MI, stroke, and other adverse effects such as hypotension and bradycardia in patients undergoing non-cardiac surgery.
Methods: A comprehensive systematic review and meta-analysis were conducted according to PRISMA 2020 guidelines.
Propranolol and landiolol inhibit cell proliferation enhanced by noradrenaline in human lung adenocarcinoma cells.
Biomed Res
November 2024
Department of Anesthesiology and Pain Medicine, Graduate School of Medicine, Nippon Medical School.
Previous clinical data have shown that perioperative β-blocker administration can improve lung cancer prognosis, possibly by blocking autonomic nervous system responses. This study aimed to investigate the anticancer mechanisms of the β-blockers propranolol and landiolol for human lung adenocarcinoma cells treated with noradrenaline. A549 human lung adenocarcinoma cells were exposed to each of the following alone or in combination for 2 h: medium only for naïve control; noradrenaline at a dose of 10 μmol/L; propranolol at 10 nmol/L; and landiolol at 1000 nmol/L.
View Article and Find Full Text PDFT17/Treg lymphocyte balance is regulated by beta adrenergic and cAMP signaling.
Brain Behav Immun
January 2025
Department of Psychiatry and Behavioral Sciences, Texas A&M University, Bryan, TX, United States; Department of Medical Physiology, Texas A&M University, Bryan, TX, United States. Electronic address:
Background: Post-traumatic stress disorder (PTSD) is a debilitating psychological disorder that also presents with neuroimmune irregularities. Patients display elevated sympathetic tone and are at an increased risk of developing secondary autoimmune diseases. Previously, using a mouse model of repeated social defeat stress (RSDS) that recapitulates certain features of PTSD, we demonstrated that elimination of sympathetic signaling to T-lymphocytes specifically limited their ability to produce pro-inflammatory interleukin 17A (IL-17A); a cytokine implicated in the development of many autoimmune disorders.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!